Ruijie Liu
About
Research
Publications
2024
Targeting KLF2 as a Novel Therapy for Glomerular Endothelial Cell Injury in Diabetic Kidney Disease.
Min L, Chen Y, Liu R, Li Z, Gu L, Mallipattu S, Das B, Lee K, He J, Zhong F. Targeting KLF2 as a Novel Therapy for Glomerular Endothelial Cell Injury in Diabetic Kidney Disease. Journal Of The American Society Of Nephrology 2024 PMID: 39382984, DOI: 10.1681/asn.0000000000000498.Peer-Reviewed Original ResearchGlomerular endothelial cell injuryEndothelial cell injuryBTBR ob/ob miceGlomerular endothelial cellsCell injuryEndothelial cellsOb/ob miceEndothelial cell-specific ablationDiabetic miceType 2 diabetic db/dbCell-specific ablationSuppressing NF-kB activationDiabetic kidney diseaseStreptozotocin-induced diabetic miceNF-kB activationImproved albuminuriaAttenuated albuminuriaMurine modelNovel therapiesNOS3 expressionDKD progressionMicrovascular diseaseDiabetic kidneyGlomerular transcriptomeKidney diseaseAccess to treatment before and after Medicare coverage of opioid treatment programs
Liu R, Beetham T, Newton H, Busch S. Access to treatment before and after Medicare coverage of opioid treatment programs. Health Affairs Scholar 2024, 2: qxae076. PMID: 38938273, PMCID: PMC11210307, DOI: 10.1093/haschl/qxae076.Peer-Reviewed Original ResearchTreatment servicesOpioid use disorderTreatment programsOpioid treatment programsMedicare coverageFor-profit statusCounty-level changesTreat opioid use disorderNonwhite residentsNonwhite populationsOpioid use disorder treatment servicesSociodemographic characteristicsNational DirectoryServicesUse disorderTreatment facilitiesOutpatient settingMedicareAccessOpioid